

Make Your Way to Market.



MINTZ LEVIN

Life Science Counsel

Representative Clients

Ascent Therapeutics
CLS Pharmaceuticals
Kinex Pharmaceuticals
Precision Pulsus
Pulmatrix
Trident Pharmaceuticals

Amedica
Archemix
Aureon Laboratories
BioProcessors
Cyclacel Pharmaceuticals
Paratek
Synvista Therapeutics
TissueLink

Alphatec Spine
Altus Pharmaceuticals
ARIAD Pharmaceuticals
Caliper Life Sciences
HealthpointCapital
Orchid Cellmark
Oxford Bioscience Partners
Panacos Pharmaceuticals

Biogen IDEC
Eli Lilly
OSI Pharmaceuticals
Qiagen GMBH
Vertex Pharmaceuticals

START UP

GO GLOBAL



Build on Your Ideas.

Biotech startup? Medical device growth company? Global life science leader? In our view, size doesn't define you; mind-set and actions do—you're driven to make a difference with your research and ideas. That drive makes you an ideal match for us. From the word "go" to the words "go public" and beyond, Mintz Levin lawyers provide business-building counsel. Companies like Biogen turned to us at the birth of the industry in 1970. Today, our life science practice is one of the deepest and largest in the country. This means that you can expect the legal resources you need at Mintz. But more than that, you'll gain an informed point of view on your business, your issues and the best way to build and expand a sustainable enterprise around your ideas.

It's a combination of skills, experience, industry relationships and like-minded thinking that draws life science organizations like yours to Mintz Levin.

FAST FACTS

500+ lawyer, 8 office AMLAW 100 firm

"A Leading Life Science Brand" – *Chambers*

One of the largest Life Science practices in the U.S.

400+ Life Science clients

Work in biotech, pharma, medical device and other medical technologies

Research

Preclinical

Phase 1

Phase 2

Phase 3

NDA

Market

Protect IP

Advise scientists and universities

Raise capital

Negotiate strategic collaborations and alliances

Build infrastructure and workforce

Complete mergers, acquisitions and innovative financings

Manage regulatory process and government relations

Navigate product launch

Defend IP and product liability lawsuits

Work Through Clinical and Other Trials.

Your innovative work to save and improve lives is your ultimate challenge, but with research and development comes issues and opportunities that can be just as demanding—and rewarding. You need to create and protect intellectual property, raise capital, manage operations, build and expand facilities, recruit and retain talent, resolve disputes and enter into complex partnerships (often with competitors). And that's just a slice of your to-do list. At the top is the health and well-being of your product development pipeline and its place in the market.

To work through these challenges, clients turn to the high-performing, interdisciplinary teams of 500+ Mintz Levin corporate, finance, IP, licensing, real estate, litigation and regulatory lawyers globally, as well as professionals from our government affairs and PR affiliate, ML Strategies.



Do a Great Deal.

Capital raising and other transactions are at the bottom line of an industry where R&D investments are made with long-term and unpredictable returns. The more capital you have, the quicker you can move. So as your company expands, you may be involved in many financings. You'll close venture rounds, complete mergers and acquisitions, enter into joint ventures and licensing agreements and even undertake multiple transactions at the same time. But each one is a critical milestone. Each needs to be executed efficiently while the opportunity is still in play. We do those deals every day. Which means we can help you find compatible partners, compare financing options, avoid unnecessary risks and maintain the flexibility to do the next deal—and the next. We'll help you remain firmly in control until you're ready to take on the next big thing.

RECENT TRANSACTIONS

128	M&A Deals, totaling \$45.2 billion
117	VC Deals, totaling \$1 billion
33	Public Offerings, totaling \$2.8 billion
51	Strategic Collaborations, totaling \$1.6 billion
168	Other Financings, totaling \$7.9 billion

Vertex
\$330 million
Follow-on
Offering

Altus
\$120 million
IPO

**Apex
Bioventures**
\$69 million
IPO

ARIAD
Collaboration
with Merck

**Caliper Life
Sciences**
\$80 million
M&A

Coley
\$110 million
IPO

QIAGEN
\$1.6 billion
M&A

**Response
Genetics**
\$21 million
IPO

**Rosetta
Genomics**
\$30 million
IPO

**Myriad
Genetics**
\$149 million
Follow-on Offering

**Transform
Pharma**
\$230 million
M&A

Tutogen
\$270 million
M&A

